DrugPatentWatch Database Preview
Agalsidase beta - Biologic Drug Details
» See Plans and Pricing
Summary for agalsidase beta
| Tradenames: | 1 |
| Patents: | 21 |
| Applicants: | 1 |
| BLAs: | 1 |
| Suppliers: see list | 1 |
| Recent Clinical Trials: | See clinical trials for agalsidase beta |
Recent Clinical Trials for agalsidase beta
Identify potential brand extensions & biosimilar entrants
| Sponsor | Phase |
|---|---|
| Sanofi | Phase 4 |
| University Hospital, Rouen | N/A |
| Amicus Therapeutics | Phase 2 |
Pharmacology for agalsidase beta
| Ingredient-type | alpha-Glucosidases |
Company Disclosures: US Patents for agalsidase beta
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genzyme | FABRAZYME | agalsidase beta | VIAL; INTRAVENOUS | 103979 | 001 | 2003-04-24 | Start Trial | Mount Sinai School of Medicine of the City of New York (New York, NY) | 2039-02-26 | RX | Orphan | company |
| Genzyme | FABRAZYME | agalsidase beta | VIAL; INTRAVENOUS | 103979 | 002 | 2003-04-24 | Start Trial | Mount Sinai School of Medicine of the City of New York (New York, NY) | 2039-02-26 | RX | Orphan | company |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
Patent Text Search: US Patents for agalsidase beta
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genzyme | FABRAZYME | agalsidase beta | VIAL; INTRAVENOUS | 103979 | 001 | 2003-04-24 | Start Trial | Momenta Pharmaceuticals, Inc. (Cambridge, MA) | 2023-10-01 | RX | Orphan | search |
| Genzyme | FABRAZYME | agalsidase beta | VIAL; INTRAVENOUS | 103979 | 001 | 2003-04-24 | Start Trial | Cell Therapeutics, Inc. (Seattle, WA) | 2025-01-25 | RX | Orphan | search |
| Genzyme | FABRAZYME | agalsidase beta | VIAL; INTRAVENOUS | 103979 | 001 | 2003-04-24 | Start Trial | Protalix Ltd. (Carmiel, IL) | 2029-11-17 | RX | Orphan | search |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patents for agalsidase beta
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Israel | 200005 | Start Trial |
| Singapore | 11201506775V | Start Trial |
| Mexico | 2007008982 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for agalsidase beta
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 0627 | Netherlands | Start Trial | PRODUCT NAME: METHOD FOR PRODUCING SECRETED PROTIENS; REGISTRATION NO/DATE: EU/1/01/188/001-006 20010803 |
| C/GB13/069 | United Kingdom | Start Trial | PRODUCT NAME: AGALSIDASE BETA; REGISTERED: UK EU/1/01/188/001 20010807; UK EU/1/01/188/002 20010807; UK EU/1/01/188/003 20010807; UK EU/1/01/188/004 20010807; UK EU/1/01/188/005 20010807; UK EU/1/01/188/006 20010807 |
| 0452 | Netherlands | Start Trial | PRODUCT NAME: AGALSIDASE ALFA; REGISTRATION NO/DATE: EU/1/01/189/001 20010807 |
| >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
